Hypocalcaemic peptides and process for their manufacture

Abstract

Human calcitonin in the form of four components and process for their isolation from C-cells material.

We claim: 
     
       1. The .Iadd.substantially pure .Iaddend.dotriacontapeptide amide of the formula ##STR3## its acid addition salts and complexes. 
     
     
       2. A pharmaceutical preparation suitable for treatment of hypercalcaemea, Paget's disease and osteoporosis comprising an effective amount of the dotriacontapeptide amide of the formula ##STR4##  .Iadd. 
     
     
       3.  The dotriacontapeptide amide of the formula Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH 2  which is substantially free of biological impurities. .Iaddend. .Iadd.4. The dotriacontapeptide amide of the formula Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH 2  which has a distribution coefficient of about 0.6 in a Craig liquid - liquid distribution system of glacial acetic acid, water and n-butanol having a volume to volume ratio of 4:1:5. .Iaddend. .Iadd.5. The dotriacontapeptide amide of the formula Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH 2  which is capable of producing a biological test activity of at least about 100 MRC units per mg in the rat calcium blood level test as described by Kumar. .Iaddend. .Iadd.6. The dotriacontrapeptide amide of the formula Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH 2  which is unitary as determined by thin layer chromatography and electrophoresis. .Iaddend. .Iadd.7. The dotriacontapeptide amide according to claim 6 wherein the thin layer chromatography is on a solid support of aluminum oxide using an eluting system of n-butanol, glacial acetic acid and water and the electrophoresis is on cellulose using an eluting system of glacial acetic 
     
     
        acid, formic acid and water. .Iaddend. .Iadd.8.  The dotriacontapeptide amide according to claim 7 wherein the reference standard for chromatographic and electrophoretic measurement of the dotriacontapeptide amide movement is porcine calcitonin. .Iaddend. .Iadd.9. A pharmaceutical preparation suitable for treatment of hypercalcaemia, Paget's disease and osteoporosis comprising an effective amount of the dotriacontapeptide amide of the formula ##STR5##.Iaddend. or its pharmaceutically acceptable acid addition salt or its formulated, activity prolonging complex in a pharmaceutical excipient 
     
     
        suitable for enteral or parenteral administration.  .Iadd.10.  A pharmaceutical preparation according to claim 9 wherein the dotriacontapeptide amide is substantially pure. .Iaddend. .Iadd.11. A pharmaceutical preparation according to claim 9 wherein the pharmaceutical carrier is mannitol. .Iaddend. .Iadd.12. A pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable formulated, activity prolonging complex of the dotriacontapeptide amide of the formula Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH 2 . .Iaddend. .Iadd.13. A pharmaceutically acceptable salt or complex according to claim 12 wherein the dotriacontapeptide amide is substantially pure. .Iaddend. .Iadd.14. A pharmaceutically acceptable acid addition salt according to 
     
     
        claim 12. .Iaddend. .Iadd.15.  A salt according to claim 14 wherein the acid is hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, stearic acid, glycollic acid, lactic acid, pyruvic acid, oxalic acid, citric acid, benzoic acid, cinnamic acid, salicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, trichloroacetic acid or trifluoroacetic acid. .Iaddend. .Iadd.16. A salt according to claim 14 wherein the acid is acetic acid. .Iaddend. .Iadd.17. A pharmaceutically acceptable, formulated activity-prolonging complex according to claim 12. .Iaddend. .Iadd.18. A complex according to claim 17 wherein the complexing substance is nonantigenic gelatin, oxypolygelatin, polyvinyl-pyrrolidone, polyphloretinephosphate phytic acid, protamine, polyglutamic acid, or an inorganic metal compound having a cation selected from aluminum, magnesium, cobalt or zinc and an anion selected from phosphate, pyrophosphate or hydroxide. .Iaddend.